Legal Failure

Showing 730 articles
Business

Bausch Health's Deep Discount: Market Overshoot or Justified Skepticism?

With shares languishing near $5.74, Bausch Health Companies (BHC) presents a stark valuation puzzle. While a standard DCF model suggests a staggering 91% undervaluation, the market's persistent sell-off reflects deep-seated concerns over the company's restructuring path and debt burden. We examine the numbers behind the divergence.

Business

Investor Exit Sparks Debate Over Corteva's Future as Breakup Talks Emerge

Hardman Johnston Global Advisors has sold its entire stake in Corteva Inc. (NYSE: CTVA) following management discussions about potentially splitting the company's Seeds and Crop Protection units. The move highlights growing investor unease over strategic direction, liability concerns, and the unclear path to value creation, casting a shadow over the agricultural giant's recent strong performance.